Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 6, 2008, Pages 1188-1190

  Garcia Diaz, Ana ^a   Blok, Chun ^a   Madge, Sara ^a   Booth, Clare ^a   Tyrer, Mervyn ^a   Bonora, Stefano ^b   Mahungu, Tabitha ^a   Owen, Andrew ^c   Johnson, Margaret ^a   Geretti, Anna Maria ^a,d  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Efavirenz clearance; Low frequency resistant mutants; Remedies

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; NEVIRAPINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; ENZYME POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MIGRATION; MUTATIONAL ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; VIRUS DETECTION; VIRUS LOAD; VIRUS MUTANT;

AMINO ACID SUBSTITUTION; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MIDDLE AGED; MUTATION, MISSENSE; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; VIRAL LOAD;

EID: 56649093042     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn374     Document Type: Article

References (10)

1. Ribaudo HJ, Haas DW, Tierney C et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42: 401-7.
2. Lundberg KS, Shoemaker DD, Adams M et al. High-fidelity amplification using a thermostable DNA polymerase isolated from Pyrococcus furiosus. Gene 1991; 108: 1-6.
3. Garcia-Diaz A, Clewley GS, Booth CL et al. Comparative evaluation of the performance of the Abbott real-time human immunodeficiency virus type 1 (HIV-1) assay for measurement of HIV-1 plasma viral load following automatic specimen preparation. J Clin Microbiol 2006; 44: 1788-91.
4. Weidle P, Malamba S, Mwebaze R et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: Patients' response, survival, and drug resistance. Lancet 2002; 360: 34-40.
5. Ciccio L. ARV treatment in poor settings: The state of the ART. Health Policy Dev 2004; 2: 52-61.
6. Julias JG, Boyer PL, McWilliams MJ et al. Mutations at position 184 of human immunodeficiency virus type-1 reverse transcriptase affect virus titer and viral DNA synthesis. Virology 2004; 322: 13-21.
7. Bacheler LT, Anton ED, Kudish P et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000; 44: 2475-84.
8. Flys T, Nissley DV, Claasen CW et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005; 192: 24-9.
9. Johnson JA, Li J-F, Wei X et al. Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS ONE 2007; 2: E638.
10. Kuritzkes DR, Lalama CM, Ribaudo HJ et al. Preexisting resistance to nonnucleoside reverse transcriptase inhibitors predicts virological failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008; 197: 867-70.